Eluciderm develops a topically administered product that facilitates scarless wound healing by reducing dermal fibrosis.
Eluciderm has raised $2.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2022.
Eluciderm is headquartered in San Diego, United States.
Eluciderm develops a topically administered product that facilitates scarless wound healing by reducing dermal fibrosis.
Eluciderm is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Eluciderm — Funding & Investors." VCBacked, April 26, 2022, https://www.vcbacked.co/company/eluciderm. Accessed August 13, 2026.
VCBacked. (2022). Eluciderm — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/eluciderm
{{cite web |title=Eluciderm — Funding & Investors |url=https://www.vcbacked.co/company/eluciderm |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated